Bringing the Oncology Community Together
European Commission Approves Ibrutinib for MCL, CLL
Ibrutinib has been approved by the European Commission for the treatment of adult patients with relapsed or refractory MCL and adult patients with CLL.
How Test Reimbursement Decisions Are Made: A Leader of Medicare’s MolDX Program Discusses Evaluation Process
Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.
Urologists in Cancer Care
The Promise of Big Data Gets Closer to Fulfillment
It seems like big data is everywhere these days. It’s being touted as a solution for physicians and practices who would like to participate in Accountable Care Organizations (ACOs) and accountable care-like contracts with payers.
Oncology Business Management
Fast Track Designation Granted to TAS-102 in mCRC
The FDA has granted a fast track designation to TAS-102 (tipiracil hydrochloride) as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the United States.
Oral Therapies Shift Treatment Paradigm in CLL
The treatment of patients with chronic lymphocytic leukemia (CLL) has undergone a dramatic transformation in the past year, with the approval of the novel oral agents ibrutinib (Imbruvica) and idelalisib (Zydelig).
New Strategies Emerge for Managing CLL Patients in Community Settings
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) is rapidly changing, with the emergence of four new therapeutic options for this malignancy in recent months.
New Treatment Strategies Emerge for Non-Small Cell Lung Cancer
The treatment of patients with non-small cell lung cancer (NSCLC) who harbor an actionable mutation in EGFR or ALK continues evolve, as clinical trials begin exploring next-generation agents and combination strategies.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.